Loading...
XSTO
ANNX
Market cap9mUSD
Aug 24, Last price  
13.20SEK
1D
0.00%
1Q
-0.38%
IPO
115.34%
Name

Annexin Pharmaceuticals AB (publ)

Chart & performance

D1W1MN
XSTO:ANNX chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-43.43%
Rev. gr., 5y
%
Revenues
0
Net income
-37m
L-26.58%
-1,387,000-5,029,000-9,830,000-30,927,000-28,847,000-28,361,000-44,240,000-52,142,000-40,726,000-44,054,000-50,252,000-36,893,000
CFO
-37m
L-26.49%
0-5,012,000-9,949,000-39,082,000-28,504,000-25,725,000-39,199,000-45,024,000-41,165,000-43,403,000-50,228,000-36,925,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
URL
https://www.annexinpharma.com/
IPO date
Apr 19, 2017
Employees
5
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT